Recent investigations have identified potential molecular markers, including DAXX/ATRX alterations in well-differentiated tumors and RB1/TP53 mutations in poorly differentiated carcinomas, which may serve as adjunctive diagnostic tools [22,23]. This evidence concerns the gene ATRX and carcinoma.